Beam insider plans sale of 25,000 shares

Beam Therapeutics filed a Form 144 notice for a planned insider stock sale.

Accepted by SEC EDGAR 01/29/2026 - 04:01 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Beam Therapeutics filed a Form 144 notice for a planned insider stock sale. The filing covers a proposed sale of 25,000 shares of common stock with an aggregate market value of $734,582.50 through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 01/29/2026.

The 25,000 shares were acquired on 01/29/2026 by exercising stock options directly from the issuer and paid for in cash. Shares of Beam Therapeutics outstanding were 101,474,944 at the time referenced, providing a baseline for the size of this planned sale.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Beam (BEAM) disclose in this Form 144 filing?

Beam discloses a planned resale of 25,000 common shares under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ with an approximate sale date of 01/29/2026 and a stated market value of $734,582.50.

How many Beam (BEAM) shares are planned to be sold and at what value?

The filing covers a proposed sale of 25,000 Beam common shares. The aggregate market value for this block is listed as $734,582.50, providing a reference for the size of the transaction relative to typical insider Rule 144 sales.

How were the Beam (BEAM) shares in this Form 144 acquired?

The 25,000 shares were acquired on 01/29/2026 via a stock option exercise from the issuer. The filing states the nature of payment as cash, indicating the option exercise was fully funded rather than paid with other forms of consideration.

Which broker will handle the planned Beam (BEAM) share sale?

The planned sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services. The broker’s listed address is 1 New York Plaza, 8th Floor, New York, NY 10004, and the securities are expected to trade on the NASDAQ exchange.

How many Beam (BEAM) shares were outstanding in this Form 144?

The filing notes that 101,474,944 Beam common shares were outstanding as referenced in the form. This figure provides context for evaluating the 25,000-share planned sale relative to the total share count in the market.

What representation does the seller make in this Beam (BEAM) Form 144?

The seller represents that they do not know any material adverse, non-public information about Beam’s current or prospective operations. This representation is a standard Rule 144 requirement tied to the good-faith nature of insider resale transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001786304
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BEAM THERAPEUTICS INC.
SEC File Number	001-39208
Address of Issuer	238 Main Street Cambridge MASSACHUSETTS 02142
Phone	(857) 327-8775
Name of Person for Whose Account the Securities are To Be Sold	JOHN M EVANS
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	25000	734582.50	101474944	01/29/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/29/2026	Stock Option Exercise	ISSUER			25000	01/29/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	01/29/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/16/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ John Martin Evans III
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)